Co se změnilo v léčbě nemocných s dyslipidemií?
| Title in English | What has changed in treatment of patients with dyslipidemia? |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Interní medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Biochemistry |
| Keywords | cardiovascular diseases; ESC/EAS guidelines 2016; LDL cholesterol; statins; ezetimibe; PCSK9 inhibitors |
| Description | Dyslipidemia is very frequent metabolic disease in general population of developed countries. Last year, the European Society of Cardiology (ESC) and European Society of Atherosclerosis (EAS) released new guidelines for management of dyslipi-daemias. In some groups of patients, the criteria for estimation of individual cardiovascular risk were changed. Recommendations for target LDL cholesterol values were also modified and this is why reaching the target level of LDL cholesterol should be now more difficult Therefore, combination of hypolipidemic drugs and using new drugs (as PCSK9 inhibitors) will be needed. Patient's compliance to long-term treatment can be improved also by a new fixed combination of hypolipidemic drugs ("polypills"). |